Report Highlights
-
The market for angiogenesis regulating agents is just emerging in 2001, with an estimated value of $100 million. It is expected to grow at an AAGR (average annual growth rate) of 88.8% to reach $2.4 billion by 2006. By 2006, angiogenesis inhibiting products are projected to represent a market approaching $1.8 billion.
-
The biggest market for angiogenesis stimulating products will be for treatment of coronary artery disease and peripheral vascular disease. Drugs for these indications are expected to begin entering the market in 2004 with the introduction of GenVec's BioByPass. This is a gene therapy-based drug for the treatment of coronary artery disease and peripheral vascular disease.
INTRODUCTION
STUDY GOAL AND OBJECTIVES
This study provides a comprehensive analysis of emerging angiogenesis regulating technologies and the impact they will have on the treatment of disease. The report focuses primarily on angiogenesis inhibitors in development for cancer treatment and angiogenesis stimulators in development for the treatment of coronary artery disease and peripheral artery disease. However, information also is provided on other diseases for which angiogenesis regulation may be applicable, including autoimmune diseases, dermatological disorders, ocular diseases and wound healing. Forecasts for the overall angiogenesis regulation market are provided. Forecasts and trends are gleaned from industry sources as well as from considered assessment of this innovative technology.
REASONS FOR DOING THE STUDY
The regulation of angiogenesis, the development of blood vessels, is an area of much activity and promise. The blocking of angiogenesis is a quickly advancing strategy in the treatment of cancer, inflammatory and dermatological diseases and eye disorders. By blocking the formation of blood vessels in tumors, tumor growth is limited to pinhead-size lesions and metastasis is prevented. The stimulation of angiogenesis is under investigation as a way of replacing blocked blood vessels in the heart and peripheral arteries. Angiogenesis stimulation also is under study for enhancing wound repair.
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
This report explains the angiogenesis process and the technologies involved in its regulation. It offers information needed to understand the impact of angiogenesis-regulating products on disease treatment, as well as how these agents will fit into clinical protocols. It is an invaluable tool for planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investor consultants and anyone interested in angiogenesis regulation, its products, its industry participants and its future.
SCOPE AND FORMAT
This report primarily focuses on products in development to treat cancer and cardiovascular diseases, with discussions of selected products directed at other diseases.
The competitive environment is examined with a special focus on how new products and technologies will likely be used in the treatment of cancer and cardiovascular diseases, i.e., will these products be used as adjuncts to, or replacement therapy for currently available products and procedures. Profiles of companies in the late stages of development of angiogenesis-regulating products are provided.
Market figures are based on revenues at the manufacturers' level and are projected at 2001 dollar value, i.e., inflation is not computed into the projection figures. Trends are assessed based on projected product sales and must necessarily be estimates, since the timing of introduction and cost of these agents is not certain. Also included in this report are forecasts through 2006, including supporting analyses for projections.
METHODOLOGY
Information for preparing this study was derived from data supplied by product managers, marketing strategists, research executives and others at leading companies involved in the development of angiogenesis regulating agents. Data was accessed from government agencies and regulatory bodies that monitor and/or regulate pharmaceutical products. Searches of secondary material such as company annual reports and 10-Ks, journal articles, prospectus assessments, government resources and data from health care institutions also were conducted.
INFORMATION SOURCES
Information for this report was obtained from companies, organizations and institutions involved in the development of angiogenesis regulating agents, industry analysts, health care personnel, The Angiogenesis Foundation, the National Cancer Institute, the American Cancer Society, the American Heart Association, the Centers for Disease Control and Prevention and other government agencies, as well as from literature searches, annual reports, 10-Ks and product literature.
Related Reports
Recent Reports
Exosome Diagnostics, Therapeutics and Research Tools: Global Markets
The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.
Peptide Synthesis: Global Markets
The global market for peptide synthesis is expected to grow from $90.1 billion in 2023 and projected to reach $157.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.8% during the forecast period of 2023 to 2028.
Oligonucleotides: Global Markets
The global market for oligonucleotides is expected to grow from $7.0 billion in 2023 and projected to reach $11.7 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2023 to 2028.
Global Market for Cell and Gene Therapy
The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028.
Viral Vector and Plasmid DNA: Technologies and Global Markets
The global market for viral vector and plasmid DNA technologies is expected to grow from $2.9 billion in 2023 to $7.1 billion by the end of 2028, at a compound annual growth rate (CAGR) of 19.7% from 2023 through 2028.
Top Trending Reports
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with a compound annual growth rate (CAGR) of 10.6% for the period of 2022-2027.
Flame Retardant Chemicals: Technologies and Global Markets
The global consumption of flame retardant chemicals is estimated to grow from 6.0 billion pounds in 2022 to 7.5 billion pounds in 2027, at a compound annual growth rate (CAGR) of 4.4% for the period of 2022-2027.
Biorefinery Products: Global Markets
The global market for biorefinery products is estimated to increase from $624.7 billion in 2022 to $920.0 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.
Electric Vehicle Charging: Infrastructure and Global Markets
The global market for wired electric vehicle charging infrastructure is estimated to grow from $24.1 billion in 2022 to $81.1 billion in 2027, at a compound annual growth rate (CAGR) of 27.4% for the period of 2022-2027.
Digital Pathology: Technologies and Global Markets
The global digital pathology market is estimated to increase from $5.9 billion in 2022 to reach $10.7 billion by 2027, at a compound annual growth rate (CAGR) of 12.5% from 2022 through 2027.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More